CurrentEndo
Get Weekly

Topic · page 6 of 12

Lipids & metabolic liver disease

Lipid disorders and metabolic dysfunction-associated steatotic (fatty) liver disease, as published in the endocrine journals

Briefs 201–240 of 460 placed here, newest publication first

Briefs in Lipids & metabolic liver disease

Newest publication first

  1. Int J Obes (Lond)

    Early childhood adiposity, lifestyle and gut microbiome are linked to steatotic liver disease development in adolescents

    Case-control study

  2. Pediatr Obes

    Association between excessive screen time and steatotic liver disease in adolescents: Findings from the 2017–2018 National Health and Nutrition Examination Survey

    Cross-sectional study

  3. Cardiovasc Diabetol

    Cholesterol, high-density lipoprotein, and glucose index versus triglyceride–glucose index in predicting cardiovascular disease risk: a cohort study

    Cohort study

  4. Cardiovasc Diabetol

    Additive association of blood group A allele with 15 cardiometabolic diseases: a UK Biobank life-course study

    Cohort study

  5. Diabetes Obes Metab

    Impact of healthy lifestyles on the risk of metabolic dysfunction‐associated steatotic liver disease among adults with comorbid hypertension and diabetes: Novel insight from a largely middle‐aged and elderly cohort in South China

    Cohort study

  6. Diabetes Obes Metab

    Joint association of remnant cholesterol and lipoprotein‐associated phospholipase A2 with composite adverse events: A 12‐year follow‐up study from Asymptomatic Polyvascular Abnormalities Community study

    Cohort study

  7. Cardiovasc Diabetol

    Relationship between atherogenic index of plasma and length of stay in critically ill patients with atherosclerotic cardiovascular disease: a retrospective cohort study and predictive modeling based on machine learning

    Cohort study

  8. Endocr Pract

    Triglyceride to High-Density Lipoprotein Cholesterol Ratio as a Marker of Subclinical Coronary Atherosclerosis and Hepatic Steatosis in Familial Hypercholesterolemia

    Cross-sectional study

  9. J Clin Endocrinol Metab

    Machine Learning–Based Biomarker Identification for Early Diagnosis of Metabolic Dysfunction–Associated Steatotic Liver Disease

    Cross-sectional study

  10. Diabetes Metab

    Association of daily sleep duration with risk of metabolic dysfunction-associated steatotic liver disease and adverse liver outcomes

    Cohort study

  11. Pediatr Obes

    Recent prevalence and trends of obesity and metabolic dysfunction‐associated steatotic liver disease (MASLD) among US adolescents: 1999 to 2020

    Cross-sectional study

  12. Endocr Pract

    Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Polycystic Ovary Syndrome in East Asia: A Review and Meta-Analysis

    Meta-analysis

  13. J Clin Endocrinol Metab

    Fetuin B Is Related to Cytokine/Chemokine and Insulin Signaling in Adipose Tissue and Plasma in Humans

    Cross-sectional study

  14. Diabetes Obes Metab

    Association of metabolic dysfunction‐associated fatty liver disease with white matter hyperintensity and cognitive decline: A longitudinal cohort study

    Cohort study

  15. Diabetes Obes Metab

    Identification of growth differentiation factor 15 as an early predictive biomarker for metabolic dysfunction‐associated steatohepatitis: A nested case–control study of UK Biobank proteomic data

    Case-control study

  16. Cardiovasc Diabetol

    Association of triglyceride-glucose related indices with mortality among individuals with MASLD combined with prediabetes or diabetes

    Cohort study

  17. Endocr Pract

    American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia

    Guideline or statement

  18. Diabetes Care

    Screening for Metabolic Dysfunction–Associated Steatotic Liver Disease–Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study

    Diagnostic or prognostic study

  19. Lancet Diabetes Endocrinol

    Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial

    Randomized controlled trial

  20. Cardiovasc Diabetol

    Correlation between atherogenic index of plasma and cardiovascular disease risk across Cardiovascular–kidney–metabolic syndrome stages 0–3: a nationwide prospective cohort study

    Cohort study

  21. Cardiovasc Diabetol

    Atherogenic index of plasma and coronary artery disease: a systematic review and meta-analysis of observational studies

    Meta-analysis

  22. Cardiovasc Diabetol

    Association between atherogenic index of plasma and future risk of cardiovascular disease in individuals with cardiovascular-kidney-metabolic syndrome stages 0–3: a nationwide prospective cohort study

    Cohort study

  23. Diabetes Obes Metab

    Apolipoprotein CIII correlates with lipoproteins in the fed state and is not regulated by leptin administration in states of hypoleptinemia induced by acute or chronic energy deficiency: Results from two randomised controlled trials

    Secondary analysis

  24. Endocr Pract

    Estimated Glucose Disposal Rate Predicts the Risk of Incident Metabolic Dysfunction-Associated Steatotic Liver Disease

    Cohort study

  25. Cardiovasc Diabetol

    Triglyceride-glucose index: carotid intima-media thickness and cardiovascular risk in a European population

    Cohort study

  26. Cardiovasc Diabetol

    Association between triglyceride-glucose (TyG) related indices and cardiovascular diseases and mortality among individuals with metabolic dysfunction-associated steatotic liver disease: a cohort study of UK Biobank

    Cohort study

  27. Diabetes Obes Metab

    Metabolic dysfunction‐associated steatotic liver disease and cancer risk: A cohort study

    Cohort study

  28. Cardiovasc Diabetol

    Triglyceride-independent associations between circulating levels of apolipoprotein C-III and biomarkers of inflammation

    Cross-sectional study

  29. Clin Endocrinol (Oxf)

    Prevalence and Predictive Features of CT‐Derived Nonalcoholic Fatty Liver Disease in Metabolically Healthy MACS

    Cross-sectional study

  30. Diabetes Res Clin Pract

    Applying 1-hour postload plasma glucose diagnostic criteria reveals high Progressive Risks of potential MASLD

    Cohort study

  31. BMJ Open Diabetes Res Care

    Beta-cell, but not autonomic nervous system, function is related to MAFLD in early stages of glucose intolerance

    Cross-sectional study

  32. Diabetes Obes Metab

    Diagnostic accuracy of Agile‐4 score for liver cirrhosis in patients with metabolic dysfunction‐associated steatotic liver disease. A systematic review and meta‐analysis of diagnostic test accuracy studies

    Meta-analysis

  33. Diabetes Res Clin Pract

    The journey of MASLD: Tracking resolution, relapse, and predictive factors after sleeve gastrectomy and one-anastomosis gastric bypass, a propensity score-matched cohort study

    Cohort study

  34. Endocr Pract

    Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter Protein-2 Inhibitors on Treating Metabolic Dysfunction-Associated Steatotic Liver Disease or Metabolic Dysfunction-Associated Steatohepatitis: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials

    Meta-analysis

  35. Pediatr Obes

    Oxidized high‐density lipoprotein and low‐density lipoprotein in adolescents with obesity and metabolic dysfunction‐associated steatotic liver disease

    Cross-sectional study

  36. Diabetes Res Clin Pract

    Type 2 diabetes and the minor allele of PNPLA3 consistently identify high-risk metabolic dysfunction associated steatotic liver disease

    Cross-sectional study

  37. J Clin Endocrinol Metab

    Associations of Cumulative Adulthood, Childhood and Lifelong Insulin With Adulthood Retinal Microvasculature

    Cohort study

  38. Diabetes Metab

    Phthalates exposure, biological aging, and increased risks of insulin resistance, prediabetes, and diabetes in adults with metabolic dysfunction-associated steatotic liver disease

    Cross-sectional study

  39. Nat Med

    Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease

    Diagnostic or prognostic study

  40. Cardiovasc Diabetol

    ApoC-III proteoforms are associated with better lipid, inflammatory, and glucose profiles independent of total apoC-III

    Cross-sectional study

All 460 Briefs in ExploreShowing Briefs 201–240 of 460, newest first